MA-BRIGHTCOVE
15.4.2024 15:01:27 CEST | Business Wire | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced the launch of its new player platforms for Roku, Samsung and LG Smart TVs. The launch of the new Software Development Kits (SDKs) has unlocked advanced features within Brightcove’s industry-leading player framework, including content protection, monetization, and analytics reporting capabilities. Designed to reduce the cost and speed of high-quality app development, media companies can more effectively target the Smart TV platforms fueling media growth while delivering a consistent, engaging premium viewer experience.
“Brightcove is committed to helping media companies deliver engaging and world-class reliable streaming experiences while reducing the costs traditionally associated with launching and running an OTT service," said Scott Levine, Chief Product Officer at Brightcove. “Our comprehensive platform enables media companies to benefit from out-of-the-box functionality and deliver premium app experiences with features previously only available in bespoke custom app development - at a fraction of the cost. "
Brightcove developed the SDKs with advertising needs in mind, supporting client-side and server-side ad insertion (CSAI, SSAI) and integrating them with digital advertising partners. Brightcove’s Roku SDK also complies with the Roku Advertising Framework (RAF), facilitating the certification process for customers. Brightcove’s Smart TV SDKs improve media handling and offer sophisticated content security capabilities, including multi-format DRM support, playback rights restrictions, and HDCP Fallback, seamlessly enabling secure delivery of premium content across all platforms.
Brightcove’s industry-leading Insights solutions also come pre-integrated. These insights, driven by the usage of the Smart TV SDKs, allow media companies to optimize ad breaks, improve player performance, identify content performance trends, pinpoint the cause of streaming quality issues, and measure impacts on viewer engagement, all to inform and enrich content, monetization and distribution strategies. The Smart TV SDKs automatically collect and report the session details impacting viewer satisfaction at scale, providing a clearer picture of overall streaming service performance and ensuring better viewer experiences.
In concert with the launch of the Smart TV SDKs, Brightcove has brought together a collection of the best video app developers to deliver options for media companies looking to meet viewers wherever they are. Partners include:
- Accedo – a global video solutions provider powering some of the world’s most impactful and engaging video-centric experiences. Accedo offers quick launch and simplified management with their Accedo One platform, or fully customizable solutions for companies looking to truly differentiate their video app experiences.
- Applicaster – helps content owners, OTT providers, and publishers connect with their audiences and drive business performance. The company’s Zapp platform is the industry’s most innovative no/low-code app management platform designed to give businesses the control, agility, and data they need to grow.
- Appsfactory – a paramount European digital agency boasting an illustrious 14-year history of crafting and deploying successful digital products and solutions.
- Arx.net/SoEasyTV – an established OTT applications provider that has developed and maintains multiple tailor-made OTT applications for large Pay TV Service Providers that support all platforms and operate with different video backend platforms. SoEasyTV OTT applications are a white-label solution that provides powerful functionalities, flexibility and a common user experience across all connected devices.
- Enveu – an end-to-end OTT technology solutions provider to build, launch, manage and grow a video streaming business across 12+ platforms, dedicated to helping media publishers and content creators.
- Pulselive – digital partner to some of the biggest names in sports, creating and powering digital experiences that engage millions of sports fans every day via digital products, including websites, mobile applications and emerging technologies.
- Spyrosoft BSG – Spyrosoft BSG (formerly known as Better Software Group) is revolutionizing digital media consumption by offering modern solutions tailored to the needs of content distributors such as broadcasters, media agencies, telecommunications companies and sports organizations.
- Robosoft Technologies – a proven digital transformation partner with a track record of crafting 10+ leading OTT streaming platforms enjoyed by millions across the globe.
- TV2Z – a global supplier of premium cloud-based OTT services that builds and launches streaming solutions across multiple devices and operators.
The Smart TV SDKs add to Brightcove’s already leading players (which currently service Web, Android, Android TV, Fire TV, iOS, iPad OS, and tvOS platforms) to propel media companies to be able to meet their audiences on any device.
For more information, visit Brightcove.com.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415787309/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
